Efficacy of pemetrexed plus a platinum rechallenge in the treatment of pleural mesothelioma

IF 0.3 Q4 ONCOLOGY
Z. Urakçı, S. Ebinç, Z. Oruç, Z. Kalkan, M. Kaplan, M. Küçüköner, A. Işıkdoğan
{"title":"Efficacy of pemetrexed plus a platinum rechallenge in the treatment of pleural mesothelioma","authors":"Z. Urakçı, S. Ebinç, Z. Oruç, Z. Kalkan, M. Kaplan, M. Küçüköner, A. Işıkdoğan","doi":"10.5603/ocp.2023.0014","DOIUrl":null,"url":null,"abstract":"Introduction. Pemetrexed-based rechallenge therapies can be used as an option in the treatment of pleural mesothelioma. We aimed to investigate the efficacy of pemetrexed-based rechallenge in mesothelioma. Material and methods. A total of 132 patients who received chemotherapy for unresectable or metastatic pleural mesothelioma in the Medical Oncology Clinic of Dicle University Medical Faculty between 2005 and 2020 were included in our study. Pemetrexed plus platinum rechallenge treatments were compared with other chemotherapy regimens in terms of survival. Results. In our study, 31 (23.4%) of a total of 132 patients received rechallenge pemetrexed plus platinum treat - ment. There was no statistically significant difference between median progression-free survival of patients who received pemetrexed plus cisplatin or gemcitabine plus cisplatin in the first-line therapy [5 months vs. 8 months (HR = 1.43; 95% CI 0.59–3.45; p = 0.376)]. In the second-line treatment, patients who received rechallenge pemetrexed plus platinum therapy had statistically significantly higher median PFS than those who received gemcitabine plus platinum [6 months vs. 4 months (HR = 0.46; 95% CI: 0.22–0.94; p = 0.011)] due to a previ - ous good response. In the second-line treatment, median overall survival was 15 months with gemcitabine plus platinum and 29 months with pemetrexed plus platinum rechallenge (p = 0.007). Conclusions. This study demonstrated that the pemetrexed plus platinum regimen was more effective than gemcitabine plus platinum in the second-line treatment in terms of both progression-free and overall survival in patients who had previously benefited from pemetrexed-based chemotherapy and had not progressed up to 6 months after first-line treatment.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"08 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2023-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology in Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/ocp.2023.0014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction. Pemetrexed-based rechallenge therapies can be used as an option in the treatment of pleural mesothelioma. We aimed to investigate the efficacy of pemetrexed-based rechallenge in mesothelioma. Material and methods. A total of 132 patients who received chemotherapy for unresectable or metastatic pleural mesothelioma in the Medical Oncology Clinic of Dicle University Medical Faculty between 2005 and 2020 were included in our study. Pemetrexed plus platinum rechallenge treatments were compared with other chemotherapy regimens in terms of survival. Results. In our study, 31 (23.4%) of a total of 132 patients received rechallenge pemetrexed plus platinum treat - ment. There was no statistically significant difference between median progression-free survival of patients who received pemetrexed plus cisplatin or gemcitabine plus cisplatin in the first-line therapy [5 months vs. 8 months (HR = 1.43; 95% CI 0.59–3.45; p = 0.376)]. In the second-line treatment, patients who received rechallenge pemetrexed plus platinum therapy had statistically significantly higher median PFS than those who received gemcitabine plus platinum [6 months vs. 4 months (HR = 0.46; 95% CI: 0.22–0.94; p = 0.011)] due to a previ - ous good response. In the second-line treatment, median overall survival was 15 months with gemcitabine plus platinum and 29 months with pemetrexed plus platinum rechallenge (p = 0.007). Conclusions. This study demonstrated that the pemetrexed plus platinum regimen was more effective than gemcitabine plus platinum in the second-line treatment in terms of both progression-free and overall survival in patients who had previously benefited from pemetrexed-based chemotherapy and had not progressed up to 6 months after first-line treatment.
培美曲塞加铂再挑战治疗胸膜间皮瘤的疗效
介绍。培美曲塞为基础的再挑战疗法可作为胸膜间皮瘤治疗的一种选择。我们的目的是研究培美曲塞在间皮瘤治疗中的疗效。材料和方法。我们的研究纳入了2005年至2020年期间在Dicle大学医学院内科肿瘤诊所接受化疗的132例不可切除或转移性胸膜间皮瘤患者。培美曲塞加铂再挑战治疗在生存方面比较了其他化疗方案。结果。在我们的研究中,总共132例患者中有31例(23.4%)接受了培美曲塞加铂的再挑战治疗。一线治疗中接受培美曲塞加顺铂或吉西他滨加顺铂的患者的中位无进展生存期差异无统计学意义[5个月vs. 8个月](HR = 1.43;95% ci 0.59-3.45;P = 0.376)]。在二线治疗中,接受再挑战培美曲塞加铂治疗的患者的中位PFS高于接受吉西他滨加铂治疗的患者[6个月vs. 4个月(HR = 0.46;95% ci: 0.22-0.94;P = 0.011)]由于先前的良好反应。在二线治疗中,吉西他滨加铂的中位总生存期为15个月,培美曲塞加铂再挑战的中位总生存期为29个月(p = 0.007)。结论。该研究表明,在二线治疗中,培美曲塞加铂方案比吉西他滨加铂方案在无进展和总生存期方面更有效,这些患者先前受益于培美曲塞为基础的化疗,并且在一线治疗后6个月内没有进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.90
自引率
20.00%
发文量
46
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信